Skip to content
Study details
Enrolling now

MDMA-Assisted Massed Exposure Therapy for PTSD

Emory University
NCT IDNCT07288151ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

200

Study length

about 4 years

Ages

21–70

Locations

1 site in GA

What this study is about

Researchers are testing if MDMA combined with Massed Prolonged Exposure (PE) therapy helps people with PTSD. The trial will compare this treatment to PE alone, and a placebo. The goal is to see if the combination of MDMA and PE leads to better results than just PE or a placebo in reducing PTSD symptoms.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Participate in Massed Prolonged Exposure (PE)
  • 2.Take 3,4-Methylenedioxymethamphetamine (MDMA)
  • 3.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug routes

oral

Endpoints

Primary: Changes in PTSD symptoms measured by CAPS-5-R

Secondary: Changes in PTSD symptoms measured by PCL-5

Body systems

Psychiatry / Mental Health